



Communication Monkeypox Diagnosis by Cutaneous and Mucosal Findings

Diogo de Sousa ^{1,*}, João Patrocínio ¹, Joana Frade ¹, Claúdia Brazão ¹, Dora Mancha ¹, Catarina Correia ¹, João Borges-Costa ^{1,2,3} and Paulo Filipe ^{1,2,4}

- ¹ Dermatology Department, Centro Hospitalar Universitário Lisboa Norte, 1169-050 Lisbon, Portugal
- ² Dermatology University Clinic, Faculty of Medicine, University of Lisbon, 1169-050 Lisbon, Portugal
 ³ Institute de Higiane e Medicine, Tropical Neura University of Lisbon 1240,008 Lisbon, Portugal
- Instituto de Higiene e Medicina Tropical, Nova University of Lisbon, 1349-008 Lisbon, Portugal
- ⁴ Dermatology Research Unit, Instituto de Medicina Molecular, University of Lisbon, 1169-050 Lisbon, Portugal
- Correspondence: 27949@chln.min-saude.pt

Abstract: A monkeypox outbreak has been reported in several countries since early May 2022. Human monkeypox (MPX) diagnosis is based on a clinical suspicion supported by typical skin and mucosal lesions, confirmed with molecular testing. We present the results of all MPX confirmed patients presenting to our department until July 15 of 2022, describing the characteristics of the lesions at diagnosis. In total, 47 patients were included, all men and 44.7% (n = 21) were HIV-positive. Skin lesions were noted in all patients. The most commonly affected area was the genital region (63.8%), followed by the anorectal region (46.8%). Extra anogenital mucosal (oral or conjunctival mucosa) involvement was reported in three patients. Typical skin findings included erythematous papules, whitish, umbilicated papules, some with a necrotic center and an elevated whitish border. Most patients had lesions is crucial to avoid late diagnosis and prevent further spreading, ensuring less worldwide morbidity.

Keywords: monkeypox; skin; epidemiology; disease outbreak



Citation: de Sousa, D.; Patrocínio, J.; Frade, J.; Brazão, C.; Mancha, D.; Correia, C.; Borges-Costa, J.; Filipe, P. Monkeypox Diagnosis by Cutaneous and Mucosal Findings. *Infect. Dis. Rep.* 2022, *14*, 759–764. https:// doi.org/10.3390/idr14050077

Academic Editor: Nicola Petrosillo

Received: 15 August 2022 Accepted: 20 September 2022 Published: 27 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

1. Introduction

Human monkeypox (MPX) is a zoonotic disease caused by the monkeypox virus (MPXV), an orthopox DNA virus related to the virus that causes smallpox. MPX is an endemic pathogen among several African countries, where most outbreaks are linked to contact with wildlife reservoirs (mainly rodents) [1,2]. The infrequently reported outbreaks in non-endemic areas usually do not extend beyond a few transmission cycles, and person-to-person transmission was rarely described [3,4].

Since early May 2022, more than 27,000 MPX cases and 11 deaths have been reported in more than 89 countries, recently inciting the World Health Organization to declare monkeypox a "Public Health Emergency of International Concern" [5,6]. Since 3 May 2022, Portuguese public health authorities have documented several cases of MPX with sustained local human-to-human transmission, summing a total of 512 cases of confirmed MPX up to 14 July 2022, with 47 cases diagnosed and managed by our center [7].

MPX clinical syndrome is commonly characterized by fever, rash or skin lesions, and lymphadenopathy [8,9]. Most patients have a moderate form of the disease with no need for hospitalization or antiviral treatment; however, described MPX complications include pneumonitis, encephalitis, keratitis, secondary bacterial infections, and deep-tissue monkeypox abscess [8,10,11].

Skin lesions are reported in the vast majority of MPX cases and constitute the predominant feature that leads to MPXV infection diagnosis. A wide spectrum of skin lesions has been described to be associated with MPX, including macular, pustular, vesicular, and crusted lesions, as well as lesions in multiple phases presenting simultaneously [8,9]. Mucosal involvement has also been described in up to 41% of MPX patients, including the anorectal, oropharyngeal, and conjunctival mucosa [9]. More atypical presentations such as single lesions, whitlows, macular eruptions, or kissing lesion configurations have also been described [11,12].

This report aims to describe the number and anatomical localization of lesions from all confirmed MPX patients attending our department with a compilation of clinical images.

2. Materials and Methods

In this retrospective, observational analysis, we reviewed the demographic and clinical characteristics of all individuals with confirmed MPXV infection diagnosed by the Department of Dermatology of Centro Hospitalar Universitário Lisboa Norte until 15 July of 2022. The lesions' number, localization, and characteristics were recorded at diagnosis. The diagnosis was confirmed with swab samples from the skin or mucosa lesions (suspected lesions at the clinician's discretion). Laboratory diagnosis was performed at the Portuguese National Sexually Transmitted Infections (STI) Reference Centre with PCR in real-time based on detecting the orthopoxvirus genus gene rpo18, followed by Sanger sequencing of PCR products from the lesions, as previously described [13].

3. Results

A total of 47 patients were included (Table 1), all men, with an average age of 35.1 years old. Regarding sexual orientation, most patients identified as men who have sex with men (MSM) (83.0%, n = 39), followed by heterosexual (8.5%; n = 4), bisexual (6.4%; n = 3), and data was missing for one patient. A total of 44.7% (n = 21) patients were people living with HIV, and 55.3% (n = 26) had previously unknown or negative HIV status.

Age	M (SD)
Years of age	35.1 (8.7)
Gender	n (%)
Men	47 (100)
Sexual orientation	n (%)
MSM	39 (83.0)
Heterosexual	4 (8.5)
Bisexual	3 (6.4)
Missing data	1 (2.1)
HIV status	n (%)
Positive	21 (44.7)
Unknown/Negative	28 (55.3)
Number of sexual partners in the last six months	n (%)
<10	38 (80.8)
>10	6 (12.7)
Missing data	3 (6.4)

Table 1. Study population.

MSM: men who have sex with men.

Skin lesions were noted in all patients (Figure 1). The most common anatomical affected sites were the genital area (63.8%; n = 30) (Figure 2A), the anorectal area (46.8%, n = 22); the trunk, arms or legs (44.7%; n = 21); and the face (27.7%; n = 13) (Figure S1). One person presented with a singular genital ulcer. Of the total patients observed, only two had more than 20 lesions at the time of observation, one of them in a disseminated pattern. Anorectal mucosa involvement was reported to be associated with anorectal pain, proctitis, or anal mucus discharge (or a combination of these symptoms). Extra anogenital



mucosal involvement was present in three patients with oral erosions (Figure 2B) and one with conjunctival mucosal involvement (Figure 2C).

Figure 1. Example of MPX papules in the trunk.




Figure 2. Example of MPX mucosal involvement. (**A**) Oral ulcerations. (**B**) Umbilicated papule in the genital mucosa. (**C**) Palpebral conjunctiva ulceration.

Typical skin findings included erythematous papules and whitish papules (Figure 3 and Figure S2). Umbilicated papules were also common, some with a necrotic center and an elevated whitish border (Figure 3F). Oral mucosa ulcers presented with well-defined borders and a clean base (Figure 2B). Most patients had lesions in multiple phases presenting simultaneously.

Common systemic features during the course of the illness included lymphadenopathy (68.1%), myalgia (55.3%), fever (53.2%), and headache (48.9%); symptoms that frequently preceded the cutaneous lesions. No patient required monkeypox-specific treatment. Most cases were mild and self-limited, and there were no deaths. One patient required hospital admission in the setting of MPX and acute HIV coinfection. The most common complications were pain and soft-tissue bacterial superinfection. The most reported post-acute complications were cicatricial lesions on the skin and post-inflammatory hyperpigmentation.




Figure 3. MPX typical skin lesions. **(A)** White papule with an erythematous halo. **(B)** Whitish papule with a necrotic center in an erythematous background. **(C)** Millimetric white papule with an erythematous halo. **(D)** White papule with erythematous background. **(E)** Millimetric whitish papule with a well-defined erythematous halo. **(F)** White umbilicated papule with a necrotic center.

4. Discussion

MPX is rapidly spreading worldwide in an unprecedented outbreak. This report provides an expansion on the clinical presentations of which health workers should be aware to diagnose MPX in a timely fashion.

Differential diagnoses of MPX lesions include other ulcerative STI—genital herpes, syphilis or chancroid—particularly when the genital and anal areas are the most affected sites [14]. However, a diagnostic clue is the absence of a typical herpetiform figuration, where vesicles are frequently seen packed closely together in genital herpes. Different from syphilis chancre, these lesions are painful, and unlike chancroid, they appear as papules that later progress to an umbilicated and ulcerative form. The papular lesions can also suggest a poxviridae infection, as seen in molluscum contagiosum (MC); or a Varicellazoster virus (VZV) infection [15,16]. However, MC lesions usually have an evolution more extended in time and are not accompanied by lymphadenopathy; and VZV is characterized not only by papules but also by vesicles and pustules in a dermatomal distribution.

Our findings confirm the previously described skin lesions associated with monkeypox are essential for a clinical diagnosis. All of our patients had skin lesions, which can be explained by the referral to our dermatology department of patients seen with skin alterations in the emergency department. Although classicaly described as a papular, vesicular, and pustular skin eruption, our data show that erythematous papules are the most commonly found lesion in MPX patients [8]. We consider that the previously described vesicles and pustules are, in fact, pseudo-pustules, with no roof to scrap and not filled with purulent material. This is also supported by the histological description of MPX lesions as keratinocytic debris and inflammatory cells but not liquid [17]. Moreover, as other authors have described, the typical dermatological MPX lesion is a papule, which can have different presentations, simultaneously or not in the same patient, with an erythematous base, umbilicated with a whitish border or a necrotic center (or a combination of these) [11].

The lesions distribution in our sample is according to previously described MPX characteristics in this outbreak [9,11], with most lesions localized in areas of close contact

during sexual intercourse. In our sample the most common anatomical affected site was the genital area, in 63.8% (n = 30) patients, a finding also described in large MPX patient series with prevalence ranging from 53% to 68% [9,11]. The second most common area with lesions was the anorectal zone in 46.8% (n = 22) patients. A singular genital ulcer was observed in one patient (2.1%), a less common presentation that can be found in up to 11% of MPX patients [11], once again reinstating the need to include MPX in the differential diagnosis of patients presenting with a singular anogenital ulcerated lesion. Two patients (4.3%) had more than 20 lesions at the time of observation, a less frequently encountered presentation that can affect up to 11% of MPX patients [9]. Both the distribution of lesions and the population characteristics (all men and most MSM) support the most commonly accepted idea that MPX seems to have an STI-like spreading pattern [9,11,14].

Clinical outcomes in this case series were reassuring, as most cases were mild, and only one patient required hospital admission, which has already been described in the literature [12]. Common systemic features encountered included lymphadenopathy (68.1%), myalgia (55.3%), fever (53.2%), and headache (48.9%); results that are in line with the most common symptom triad described in MPX patients besides skin/mucosal lesions: lymphadenopathy, fever and asthenia/lethargy [9,11]. Patients with severe disease or at risk for severe disease include those with mucosal or significant anogenital involvement [18]. These patients appear to be more symptomatic, with painful and eroded lesions, and have a higher number of complications, particularly superimposed bacterial skin infection [18].

Correct identification of MPX skin and mucosal lesions is fundamental for a timely MPX diagnosis in order to provide appropriate management of these patients, prevent further dissemination, and decrease the risk for MPX complications, ensuring less worldwide morbidity.

5. Conclusions

Our findings aim at improving MPX case recognition and definition, infection control policies, contact tracing, and future management. Long-term clinical data will help to describe risk factors associated with sequelae, complications of infection, and outcomes in patients living with HIV or presenting with other comorbidities. Further studies are needed to support MPX management and describe the wide clinical presentations occurring during this outbreak in order to decrease onward virus transmission, making use of strategies such as health promotion, preventative or post-exposure vaccination, and antiviral therapy.

Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/idr14050077/s1, Figure S1: Examples of MPX skin involvement. (A) Whitish papule with necrotic center and an erythematous halo on the gluteal area. (B) Erythematous papules on the neck. (C) Erythematous papules on the chest. (D) Whitish perianal papules. (E) Whitish papule on the thigh. (F) Erythematous papules on the palm, Figure S2: MPX typical skin lesions. (A) Whitish papules with an erythematous halo. (B) Confluent papules with necrotic center and whitish borders in an erythematous background. (C) Whitish papules, some with necrotic center. (D) Whitish umbilicated papules with necrotic center.

Author Contributions: D.d.S., J.P., J.F., C.B., D.M., C.C., J.B.-C. and P.F. contributed equally to the conceptualization, data curation, writing—review and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, as revised in 2013. Ethical approval was not required due to communicable disease outbreak investigations in the public interest.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors would like to thank Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) for the help provided in diagnosing MPX cases.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Hutin, Y.J.F.; Williams, R.J.; Malfait, P.; Pebody, R.; Loparev, V.N.; Ropp, S.L.; Rodriguez, M.; Knight, J.C.; Tshioko, F.K.; Khan, A.S.; et al. Outbreak of Human Monkeypox, Democratic Republic of Congo, 1996 to 1997. *Emerg. Infect. Dis.* 2001, 7, 434–438. [CrossRef] [PubMed]
- Wilson, M.E.; Hughes, J.M.; McCollum, A.M.; Damon, I.K. Human Monkeypox. *Clin. Infect. Dis. Clin. Infect. Dis.* 2014, 58, 260–267. Available online: https://pubmed.ncbi.nlm.nih.gov/24158414/ (accessed on 3 June 2022).
- Reed, K.D.; Melski, J.W.; Graham, M.B.; Regnery, R.L.; Sotir, M.J.; Wegner, M.V.; Kazmierczak, J.J.; Stratman, E.J.; Li, Y.; Fairley, J.A.; et al. The detection of Monkeypox in humans in the Western Hemisphere. *N. Engl. J. Med.* 2004, 350, 342–350. Available online: https://pubmed.ncbi.nlm.nih.gov/14736926/ (accessed on 3 June 2022). [CrossRef]
- 4. Di Giulio, D.B.; Eckburg, P.B. Human Monkeypox: An emerging zoonosis. *Lancet Infect. Dis.* **2004**, *4*, 15–25. Available online: https://pubmed.ncbi.nlm.nih.gov/14720564/ (accessed on 3 June 2022). [CrossRef]
- World Health Organization. Multi-Country Outbreak of Monkeypox, External Situation Report #3–10 August 2022. Available online: https://www.who.int/publications/m/item/multi-country-outbreak-of-monkeypox--external-situation-report--3---1 0-august-2022 (accessed on 11 August 2022).
- World Health Organization. Second Meeting of the International Health Regulations (2005) (IHR) Emergency Committee Regarding the Multi-Country Outbreak of Monkeypox. 2022. Available online: https://www.who.int/news/item/23-07-20 22-second-meeting-of-the-international-health-regulations-(2005)-(ihr)-emergency-committee-regarding-the-multi-countryoutbreak-of-monkeypox (accessed on 24 July 2022).
- DGS. Infeção Humana por Vírus Monkeypox em Portugal. Available online: https://www.dgs.pt/em-destaque/informacaosemanal-sobre-infecao-humana-por-virus-monkeypox-n-002-pdf.aspx (accessed on 11 August 2022).
- Huhn, G.D.; Bauer, A.M.; Yorita, K.; Graham, M.B.; Sejvar, J.; Likos, A.; Damon, I.K.; Reynolds, M.G.; Kuehnert, M.J. Clinical characteristics of human monkeypox, and risk factors for severe disease. *Clin. Infect. Dis.* 2005, *41*, 1742–1751. Available online: https://pubmed.ncbi.nlm.nih.gov/16288398/ (accessed on 6 June 2022). [CrossRef] [PubMed]
- Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; et al. Monkeypox Virus Infection in Humans across 16 Countries—April–June 2022. N. Engl. J. Med. 2022, 387, 679–691. Available online: https://pubmed.ncbi.nlm.nih.gov/35866746/ (accessed on 24 July 2022). [CrossRef]
- Adler, H.; Gould, S.; Hine, P.; Snell, L.B.; Wong, W.; Houlihan, C.F.; Osborne, J.C.; Rampling, T.; Beadsworth, M.B.; Duncan, C.J.; et al. Clinical features and management of human monkeypox: A retrospective observational study in the UK. *Lancet Infect. Dis.* 2022, 22, 1153–1162. Available online: http://www.ncbi.nlm.nih.gov/pubmed/35623380 (accessed on 6 June 2022). [CrossRef]
- Català, A.; Clavo Escribano, P.; Riera, J.; Martín-Ezquerra, G.; Fernandez-Gonzalez, P.; Revelles-Peñas, L.; Simon-Gozalbo, A.; Rodríguez-Cuadrado, F.J.; Castells, V.G.; de la Torre Gomar, F.J.; et al. Monkeypox outbreak in Spain: Clinical and epidemiological findings in a prospective cross-sectional study of 185 cases. *Br. J. Dermatol.* 2022, *online ahead of print*. Available online: https://pubmed.ncbi.nlm.nih.gov/35917191/ (accessed on 10 August 2022). [CrossRef] [PubMed]
- de Sousa, D.; Patrocínio, J.; Frade, J.; Correia, C.; Borges-Costa, J.; Filipe, P. Human monkeypox coinfection with acute HIV: An exuberant presentation. *Int. J. STD AIDS* 2022, *33*, 095646242211149. Available online: https://pubmed.ncbi.nlm.nih.gov/358229 10/ (accessed on 10 August 2022). [CrossRef] [PubMed]
- Perez Duque, M.; Ribeiro, S.; Martins, J.V.; Casaca, P.; Leite, P.P.; Tavares, M.; Mansinho, K.; Duque, L.M.; Fernandes, C.; Cordeiro, R.; et al. Ongoing monkeypox virus outbreak, Portugal, Apr 29 to May 23, 2022. *Eurosurveillance* 2022, 27, 2200424. Available online: https://pubmed.ncbi.nlm.nih.gov/35656830/ (accessed on 3 June 2022). [CrossRef] [PubMed]
- Alpalhão, M.; Frade, J.; Sousa, D.; Patrocínio, J.; Garrido, P.; Correia, C.; Brazão, C.; Mancha, D.; Borrego, M.; Filipe, P. Monkeypox: A new (sexually transmissible) epidemic? *J. Eur. Acad. Dermatol. Venereol.* 2022. Available online: https: //onlinelibrary.wiley.com/doi/full/10.1111/jdv.18424 (accessed on 25 July 2022). [CrossRef] [PubMed]
- Edwards, S.; Boffa, M.; Janier, M.; Calzavara-Pinton, P.; Rovati, C.; Salavastru, C.; Rongioletti, F.; Wollenberg, A.; Butacu, A.; Skerlev, M.; et al. 2020 European guideline on the management of genital molluscum contagiosum. *J. Eur. Acad. Dermatol. Venereol.* 2020, 35, 17–26. Available online: https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16856 (accessed on 12 September 2022). [CrossRef] [PubMed]
- Gross, G.E.; Eisert, L.; Doerr, H.W.; Fickenscher, H.; Knuf, M.; Maier, P.; Maschke, M.; Müller, R.; Pleyer, U.; Schäfer, M.; et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. *JDDG J. Dtsch. Dermatol. Ges.* 2019, 18, 55–78. Available online: https://pubmed.ncbi.nlm.nih.gov/31951098/ (accessed on 12 September 2022). [CrossRef] [PubMed]
- 17. Bayer-Garner, I.B. Monkeypox virus: Histologic, immunohistochemical and electron-microscopic findings. *J. Cutan. Pathol.* 2005, 32, 28–34. Available online: https://pubmed.ncbi.nlm.nih.gov/15660652/ (accessed on 11 August 2022). [CrossRef] [PubMed]
- Tarín-Vicente, E.J.; Alemany, A.; Agud-Dios, M.; Ubals, M.; Suñer, C.; Antón, A.; Arando, M.; Arroyo-Andrés, J.; Calderón-Lozano, L.; Casañ, C. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: A prospective observational cohort study. *Lancet* 2022, 400, 661–669. Available online: http://www.thelancet.com/article/S0140673622014362/ fulltext (accessed on 12 September 2022). [CrossRef]